Taxotere Will Benefit From "Average Sales Price" Reimbursement
This article was originally published in The Pink Sheet Daily
Executive SummaryAventis expects Taxotere's performance in the U.S. to receive a boost from the implementation of "average sales price" reimbursement under Medicare in 2005
You may also be interested in...
The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.
Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.
Latest effort by FDA to re-set reviews for novel opioid analgesics is off to a rocky start after three advisory committee reviews. One unintended consequences may already be apparent: by taking a broad, public health perspective on new formulations, the agency may be inviting arguments based on price.